Cartesian Therapeutics Soars 4.93% Post-Q1 2025 Results!

Cartesian Therapeutics, Inc. rose 4.93% in after-hours trading, following the release of its first-quarter results for the period ending March 31, 2025. The company reported a revenue of $1.1 million, down from $5.84 million in the previous year, and a net loss of $17.71 million, compared to $56.82 million in the prior year. The decrease in net loss and the company's ongoing operations may have contributed to the positive market sentiment.